|
May 5
|
Inventiva secures the €116 million second tranche of its structured financing of up to €348 million
|
|
Apr 30
|
Statement of total voting rights and shares forming the company’s share capital as of April 11, 2025
|
|
Apr 30
|
Combined General Meeting of May 22, 2025 - Availability of the preparatory documents
|
|
Feb 20
|
Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial
|
|
Feb 10
|
Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update
|